Literature DB >> 28324197

The spectrum of magnetic resonance findings in cerebrotendinous xanthomatosis: redefinition and evidence of new markers of disease progression.

Andrea Mignarri1, Maria Teresa Dotti2, Antonio Federico1, Nicola De Stefano1, Marco Battaglini1, Irene Grazzini3, Paolo Galluzzi3, Lucia Monti3.   

Abstract

Cerebrotendinous xanthomatosis (CTX) is a metabolic disease characterized by systemic signs and neurological impairment, which can be prevented if chenodeoxycholic acid (CDCA) treatment is started early. Despite brain MRI represents an essential diagnostic tool, the spectrum of findings is worth to be reappraised, and follow-up data are needed. We performed clinical evaluation and brain MRI in 38 CTX patients. Sixteen of them who were untreated at baseline examination underwent clinical and MRI follow-up after long-term treatment with CDCA. Brain MRI abnormalities included cortical and cerebellar atrophy, and T2W/FLAIR hyperintensity involving subcortical, periventricular, and cerebellar white matter, the brainstem and the dentate nuclei. Regarding the dentate nuclei, we also observed T1W/FLAIR hypointensity consistent with cerebellar vacuolation and T1W/FLAIR/SW hypointense alterations compatibly with calcification in a subgroup of patients. Long-term follow-up showed that clinical and neuroradiological stability or progression were almost invariably associated. In patients with cerebellar vacuolation at baseline, a worsening over time was observed, while subjects lacking vacuoles were clinically and neuroradiologically stable at follow-up. The brains of CTX patients very often show both supratentorial and infratentorial abnormalities at MRI, the latter being related to clinical disability and including a wide spectrum of dentate nuclei alterations. The presence of cerebellar vacuolation may be regarded as a useful biomarker of disease progression and unsatisfactory response to therapy. On the other hand, the absence of dentate nuclei signal alteration should be considered an indicator of better prognosis.

Entities:  

Keywords:  Cerebellar vacuolation; Cerebrotendinous xanthomatosis; Chenodeoxycholic acid; Dentate nuclei; MRI

Mesh:

Year:  2017        PMID: 28324197     DOI: 10.1007/s00415-017-8440-0

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  29 in total

1.  Cerebrotendinous xanthomatosis with progressive cerebellar vacuolation : six-year MRI follow-up.

Authors:  Andrea Mignarri; Maria Teresa Dotti; Marina Del Puppo; Gian Nicola Gallus; Antonio Giorgio; Alfonso Cerase; Lucia Monti
Journal:  Neuroradiology       Date:  2012-03-15       Impact factor: 2.804

2.  Clinical imaging and neuropathological correlations in an unusual case of cerebrotendinous xanthomatosis.

Authors:  D Wallon; L Guyant-Maréchal; A Laquerrière; R A Wevers; O Martinaud; L A J Kluijtmans; H G Yntema; P Saugier-Veber; D Hannequin
Journal:  Clin Neuropathol       Date:  2010 Nov-Dec       Impact factor: 1.368

3.  Consensus paper: the cerebellum's role in movement and cognition.

Authors:  Leonard F Koziol; Deborah Budding; Nancy Andreasen; Stefano D'Arrigo; Sara Bulgheroni; Hiroshi Imamizu; Masao Ito; Mario Manto; Cherie Marvel; Krystal Parker; Giovanni Pezzulo; Narender Ramnani; Daria Riva; Jeremy Schmahmann; Larry Vandervert; Tadashi Yamazaki
Journal:  Cerebellum       Date:  2014-02       Impact factor: 3.847

4.  Interobserver agreement for the assessment of handicap in stroke patients.

Authors:  J C van Swieten; P J Koudstaal; M C Visser; H J Schouten; J van Gijn
Journal:  Stroke       Date:  1988-05       Impact factor: 7.914

5.  Cholestanol induces apoptosis of cerebellar neuronal cells.

Authors:  K Inoue; S Kubota; Y Seyama
Journal:  Biochem Biophys Res Commun       Date:  1999-03-05       Impact factor: 3.575

6.  Neurological outcome in cerebrotendinous xanthomatosis treated with chenodeoxycholic acid: early versus late diagnosis.

Authors:  Gilad Yahalom; Rakefet Tsabari; Noa Molshatzki; Lilach Ephraty; Hofit Cohen; Sharon Hassin-Baer
Journal:  Clin Neuropharmacol       Date:  2013 May-Jun       Impact factor: 1.592

7.  Long-term treatment of cerebrotendinous xanthomatosis with chenodeoxycholic acid.

Authors:  V M Berginer; G Salen; S Shefer
Journal:  N Engl J Med       Date:  1984-12-27       Impact factor: 91.245

Review 8.  Atypical parkinsonism and cerebrotendinous xanthomatosis: report of a family with corticobasal syndrome and a literature review.

Authors:  Ignacio Rubio-Agusti; Maja Kojovic; Mark J Edwards; Elaine Murphy; Hoskote S Chandrashekar; Robin H Lachmann; Kailash P Bhatia
Journal:  Mov Disord       Date:  2012-11-02       Impact factor: 10.338

9.  The neuropathology of cerebrotendinous xanthomatosis revisited: a case report and review of the literature.

Authors:  D Soffer; D Benharroch; V Berginer
Journal:  Acta Neuropathol       Date:  1995       Impact factor: 17.088

10.  On the mechanism of cerebral accumulation of cholestanol in patients with cerebrotendinous xanthomatosis.

Authors:  Ute Panzenboeck; Ulla Andersson; Magnus Hansson; Wolfgang Sattler; Steve Meaney; Ingemar Björkhem
Journal:  J Lipid Res       Date:  2007-02-26       Impact factor: 5.922

View more
  16 in total

Review 1.  The current role of MRI in differentiating multiple sclerosis from its imaging mimics.

Authors:  Ruth Geraldes; Olga Ciccarelli; Frederik Barkhof; Nicola De Stefano; Christian Enzinger; Massimo Filippi; Monika Hofer; Friedemann Paul; Paolo Preziosa; Alex Rovira; Gabriele C DeLuca; Ludwig Kappos; Tarek Yousry; Franz Fazekas; Jette Frederiksen; Claudio Gasperini; Jaume Sastre-Garriga; Nikos Evangelou; Jacqueline Palace
Journal:  Nat Rev Neurol       Date:  2018-03-09       Impact factor: 42.937

2.  Treatment with chenodeoxycholic acid in cerebrotendinous xanthomatosis: clinical, neurophysiological, and quantitative brain structural outcomes.

Authors:  Maria Del Mar Amador; Marion Masingue; Rabab Debs; Foudil Lamari; Vincent Perlbarg; Emmanuel Roze; Bertrand Degos; Fanny Mochel
Journal:  J Inherit Metab Dis       Date:  2018-03-20       Impact factor: 4.982

3.  CYP27A1 mutation in a case of cerebrotendinous xanthomatosis: A case report.

Authors:  Zhao-Ran Li; Yu-Ling Zhou; Qi Jin; Yin-Yin Xie; Hong-Mei Meng
Journal:  World J Clin Cases       Date:  2022-06-26       Impact factor: 1.534

4.  Autism spectrum disorder: an early and frequent feature in cerebrotendinous xanthomatosis.

Authors:  Bianca M L Stelten; Olivier Bonnot; Hidde H Huidekoper; Francjan J van Spronsen; Peter M van Hasselt; Leo A J Kluijtmans; Ron A Wevers; Aad Verrips
Journal:  J Inherit Metab Dis       Date:  2017-09-11       Impact factor: 4.982

5.  Brain diffusion tensor imaging changes in cerebrotendinous xanthomatosis reversed with treatment.

Authors:  Claudia B Catarino; Christian Vollmar; Clemens Küpper; Klaus Seelos; Constanze Gallenmüller; Joanna Bartkiewicz; Saskia Biskup; Konstanze Hörtnagel; Thomas Klopstock
Journal:  J Neurol       Date:  2017-12-19       Impact factor: 4.849

Review 6.  Conventional MRI findings in hereditary degenerative ataxias: a pictorial review.

Authors:  Sirio Cocozza; Giuseppe Pontillo; Giovanna De Michele; Martina Di Stasi; Elvira Guerriero; Teresa Perillo; Chiara Pane; Anna De Rosa; Lorenzo Ugga; Arturo Brunetti
Journal:  Neuroradiology       Date:  2021-03-17       Impact factor: 2.804

7.  c.1263+1G>A Is a Latent Hotspot for CYP27A1 Mutations in Chinese Patients With Cerebrotendinous Xanthomatosis.

Authors:  Jingwen Jiang; Guang Chen; Jingying Wu; Xinghua Luan; Haiyan Zhou; Xiaoli Liu; Zeyu Zhu; Xiaoxuan Song; Shige Wang; Xiaohang Qian; Juanjuan Du; Xiaojun Huang; Mei Zhang; Wei Xu; Li Cao
Journal:  Front Genet       Date:  2020-07-01       Impact factor: 4.599

8.  A Treatable Rare Cause of Progressive Ataxia and Palatal Tremor.

Authors:  Malco Rossi; Martin Cesarini; Emilia M Gatto; Angel Cammarota; Marcelo Merello
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2018-05-17

Review 9.  Childhood-onset hereditary spastic paraplegia and its treatable mimics.

Authors:  Darius Ebrahimi-Fakhari; Afshin Saffari; Phillip L Pearl
Journal:  Mol Genet Metab       Date:  2021-06-24       Impact factor: 4.797

10.  Evaluation of the effect of chenodeoxycholic acid treatment on skeletal system findings in patients with cerebrotendinous xanthomatosis.

Authors:  Tanyel Zübarioğlu; İnci Pınar Bilen; Ertugrul Kıykım; Beyza Belde Doğan; Ece Öge Enver; Mehmet Şerif Cansever; Ayşe Çiğdem Aktuğlu Zeybek
Journal:  Turk Pediatri Ars       Date:  2019-07-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.